Clinical relapse · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower clinical relapse compared with placebo (moderate certainty).
1 finding from 1 review
Endoscopic relapse · Patients with moderately to severely active ulcerative colitis
Vedolizumab probably leads to lower endoscopic relapse compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · Patients with moderately to severely active ulcerative colitis
Vedolizumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · Patients with moderately to severely active ulcerative colitis
Vedolizumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Peripheral health centre with a prior probability of disease of 40% · Patients suspected to have visceral leishmaniasis disease 1
1 finding from 1 review
Intervention not reported
Referral centre with a prior probability of disease of 60% · Patients suspected to have visceral leishmaniasis disease 1
1 finding from 1 review
Intervention not reported
CI: confidence interval · Patients suspected to have visceral leishmaniasis disease 1
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Peripheral health centre with a prior probability of disease of 40% · Patients suspected to have visceral leishmaniasis disease 1
1 finding from 1 review
Intervention not reported
Referral centre with a prior probability of disease of 60% · Patients suspected to have visceral leishmaniasis disease 1
1 finding from 1 review
Intervention not reported
CI: confidence interval · Patients suspected to have visceral leishmaniasis disease 1
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Peripheral health centre with a prior probability of disease of 40% · Patients suspected to have visceral leishmaniasis disease 1
1 finding from 1 review
Intervention not reported
Referral centre with a prior probability of disease of 60% · Patients suspected to have visceral leishmaniasis disease 1
1 finding from 1 review
Intervention not reported
CI: confidence interval · Patients suspected to have visceral leishmaniasis disease 1
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptomatic remission · Patients with quiescent ulcerative colitis
Rectal 5‐ASA may leads to higher symptomatic remission compared with placebo (low certainty).
1 finding from 1 review
Symptomatic remission · Patients with quiescent ulcerative colitis
Rectal 5‐ASA showed no clear difference in symptomatic remission compared with oral 5‐ASA (low certainty).
1 finding from 1 review
Endoscopic remission · Patients with quiescent ulcerative colitis
Rectal 5‐ASA showed no clear difference in endoscopic remission compared with oral 5‐ASA (low certainty).
1 finding from 1 review
Relapse at 6 months Clinical Disease Activty Index more than 42 · Maintenance of remission in ulcerative colitis
Curcumin showed no clear difference in relapse at 6 months Clinical Disease Activty Index more than 42 compared with placebo (low certainty).
1 finding from 1 review
Relapse at 12 months Clinical Disease Activty Index more than 42 · Maintenance of remission in ulcerative colitis
Curcumin showed no clear difference in relapse at 12 months Clinical Disease Activty Index more than 42 compared with placebo (low certainty).
1 finding from 1 review
Disease activity · Maintenance of remission in ulcerative colitis
1 finding from 1 review
Endoscopic Index at 6 months Endoscopic Index9. Scale from: 1 to 4. · Maintenance of remission in ulcerative colitis
1 finding from 1 review